Given that NSC632839 specifically destabilizes DDR1 by targeting USP7 in vitro and ex vivo, and demonstrates significant in vivo efficacy in the A549-CDX model, we further evaluated its impact on the growth of TP53-mutant, DDR1-positive DLBCL in vivo. This evidence concerns the gene TP53 and diffuse large B-cell lymphoma.